阿替唑单抗
彭布罗利珠单抗
医学
三阴性乳腺癌
肿瘤科
内科学
乳腺癌
安慰剂
佐剂
癌症
免疫疗法
病理
替代医学
作者
Farah Latif,Hira Bint Abdul Jabbar,Hamna Malik,Humaira Sadaf,Azza Sarfraz,Zouina Sarfraz,Iván Chérrez-Ojeda
标识
DOI:10.1080/14737140.2022.2023011
摘要
We collate evidence of atezolizumab/pembrolizumab as viable therapeutics among patients with TNBC with PD-L1 subgroups deriving higher benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI